0A3S Stock Chart & Stats
$7.52
-$0.24(-3.11%)
At close: 4:00 PM EDT
$7.52
-$0.24(-3.11%)
Day’s Range― - ―
52-Week Range$6.16 - $11.97
Previous CloseN/A
Volume32.31K
Average Volume (3M)53.74K
Market Cap
$1.20B
Enterprise Value$833.79
Total Cash (Recent Filing)$719.34M
Total Debt (Recent Filing)$297.32M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,438,130
10 Day Avg. Volume36,085
30 Day Avg. Volume53,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.33Price Target Upside50.71% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$412.96M
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipsA broad set of nonexclusive licenses, MTAs and a Pfizer upfront create durable commercialization avenues and de-risk R&D. Partner deals provide milestone and royalty potential, extend the reach of Matrix‑M, and convert fixed R&D spend into partner-funded development and recurring revenues over multiple years.
Strong Cash RunwayA sizable cash and receivable balance plus nondilutive inflows and a credit draw provide multi-year runway, easing near-term financing pressure. That liquidity supports IND-enabling studies, partner collaborations, and execution of the cost-reduction roadmap without immediate equity dilution.
Differentiated Adjuvant/reactogenicityEvidence of favorable reactogenicity for Matrix‑M–adjuvanted vaccines supports a structural competitive advantage: better tolerability can boost adoption in certain populations and strengthen partner interest, aiding long-term licensing, market share in niche segments, and positioning against mRNA competitors.
Bears Say
Negative EquityA recurring equity deficit signals accumulated losses and weak solvency metrics, which can elevate perceived leverage, limit borrowing terms, and increase the likelihood of dilutive financing. Over the medium term this constrains strategic flexibility and raises stakeholder scrutiny on capital structure choices.
Weak Cash GenerationSustained negative operating and free cash flow means core operations do not yet self-fund growth. Continued reliance on partner receipts, credit facility draws or other financing elevates execution risk: if partner payments slow, funding R&D or reaching profitability targets could require dilutive capital raises.
Dependence On Partners And Low Direct SalesLow direct product sales and reliance on converting MTAs into licensed partnerships mean revenue realization is contingent on external partner decisions and milestones. This dependency creates timing risk for milestone receipts and royalties, complicating the path to stable, predictable revenue and profitability.
Novavax News
0A3S FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest share price was $6.16 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.20B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.06.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.13.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went down -0.654%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in GB:0A3S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$11.33 (50.71% Upside)
$11.33 (50.71% Upside)
Blogger Sentiment
Bullish
GB:0A3S Sentiment 91%
Sector Average 63%
Sector Average 63%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
0A3S Company Deck
0A3S Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all GB:0A3S earnings summaries0A3S Stock 12 Month Forecast
Average Price Target
$11.33
▲(50.71% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―